- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03878420
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE II)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. The target enrollment is 96 subjects in up to 10 centers in Europe, randomized at a 1:2 ratio into 2 groups: Sham Treatment (S-1) and PBM Treatment (T-2). Once 96 subjects have been enrolled in the study, if there are less than 144 eyes that qualify for the study, additional subjects will be enrolled until 144 eyes have been included in the study.
S-1 will receive 3 sham treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4 and 8. T-2 will receive 3 PBM treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4 and 8. Each treatment series will total 9 treatments. Neither the subject nor the study staff will know which treatment the subject has been assigned.
Subjects will receive standard visual outcome measurements including Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA, CSV-1000E contrast sensitivity (CS) and the Radner Reading Test prior to and following each treatment series as well as eye exams, fundus photographs, Heidelberg OCT and FAF imaging and optional Optos Ultra Wide Field (UWF) imaging of the retina at selected time intervals. Subjects will also complete the Visual Function Questionnaire 25 (VFQ-25) at selected time intervals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nantes, France
- Institut ophtalmologique de l'Ouest- Clinique jules VERNE
-
-
-
-
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg- Klinik für Augenheilkunde
-
Kiel, Germany
- Klinik fur Ophthalmologie, Universitatsklinikum Schleswig-Holstein
-
Mainz, Germany, 55131
- Universitaetsmedizin Mainz- Augenklinik
-
-
-
-
-
Milano, Italy
- Osprdalr San Raffaele
-
-
-
-
-
Barcelona, Spain
- Institut Catala de Retina
-
-
-
-
-
Great Yarmouth, United Kingdom, NR31 6LA
- James Paget University
-
Peterborough, United Kingdom, PE3 9GZ
- Peterborough City Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female at least 50 years of age at Screening visit
- Subjects with ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to 20/32). *If the subject meets this criterion at the Screening Visit but is outside the letter score by up to two letters at Baseline, the subject may be entered in the study.
- Subjects with a diagnosis of dry AMD as defined by the presence of drusen (regular or reticular pseudodrusen) and/or geographic atrophy (GA) visible on two of the following: color fundus images, OCT and/or Heidelberg FAF
- Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
- Subject is informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines
Exclusion Criteria:
Current or history of neovascular maculopathy that includes any of the following:
- Choroidal neovascularization (CNV) defined as pathologic angiogenesis originating from the choroidal vasculature that extends through a defect in Bruch's membrane
- Serous and/or hemorrhagic detachment of the neurosensory retina or retinal pigment epithelial (RPE)
- Retinal hard exudates (a secondary phenomenon resulting from chronic intravascular leakage)
- Subretinal and sub-RPE fibrovascular proliferation
- Disciform scar (subretinal fibrosis)
- Presence of center involving GA within the central ETDRS 1 mm diameter at Screening
- Media opacities, including cataracts, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the next 24 months.
- Posterior capsule opacification, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require surgery in the study eye in the next 24 months
- Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3 months prior to Screening
- Ocular disorder or disease that partially or completely obstructs the pupil (e.g. posterior synechia in uveitis)
- Visually significant disease in any ocular structure apart from dry AMD (e.g. diabetic macular edema, glaucoma (using >2 eye drop medications, uncontrolled IOP and/or central/paracentral visual field loss), glaucoma surgery, active uveitis, active vitreous disease, intraocular tumor, retinal vascular diseases)
- Has a serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study
- Presence of or history of malignancy within the past 5 years other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ
- Is non-ambulatory
- Presence or history of known light sensitivity to yellow light, red light, or near infrared radiation (NIR), or if there is a history of light activated CNS disorders (e.g. epilepsy, migraine)
- Use of any photosensitizing agent (e.g. topicals, injectables) within 30 days of treatment without consulting subject's physician
- History of drug, alcohol or substance abuse within 3 months prior to Screening
- Has received an investigational drug or treatment with an investigational device within 3 months prior to Screening
- If on any anti-oxidant or vitamin Age-Related Eye Disease Study (AREDS) supplement for dry AMD, has not been stabilized for a minimum of 1 month prior to Screening. Subjects are considered to be stable if they are taking the AREDS supplements consistently as prescribed by their treating doctor.
- Has received Low Vision Rehab/Therapy within 30 days prior to Screening or intends to receive during the study
- In the opinion of the Investigator, is unlikely to comply with the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PBM Treatment
The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
|
The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye.
The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together.
The 660 nm wavelength will be treated through the closed eyelid.
|
Sham Comparator: Sham Treatment
The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
|
The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light.
The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Corrected Visual Acuity
Time Frame: Month 9
|
The primary efficacy endpoint will be the change in BCVA from Baseline to Month 9 as assessed using the ETDRS BCVA chart.
|
Month 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Corrected Visual Acuity
Time Frame: Month 9
|
The first of the secondary analyses will test the difference between the sham-treated and PBM-treated subjects in mean change from baseline (pre-treatment) to Month 9 in BCVA.
|
Month 9
|
Contrast Sensitivity
Time Frame: Month 9
|
The second of the secondary analyses will test the difference between the sham-treated and PBM-treated subjects in mean change from baseline (pre-treatment) to Month 9 in contrast sensitivity at 18 cycles/degree (CPD).
|
Month 9
|
Impact on Central Drusen Volume by OCT
Time Frame: Month 10
|
The analyses will first examine change from the screening visit in central Drusen volume
|
Month 10
|
Impact on Central Drusen Thickness by OCT
Time Frame: Month 10
|
The analyses will then examine change from the screening visit in central Drusen Thickness
|
Month 10
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Age-related Macular Degeneration
-
LumiThera, Inc.RecruitingDry Age-related Macular DegenerationNorway
-
LumiThera, Inc.National Eye Institute (NEI)RecruitingDry Age-related Macular DegenerationUnited States
-
Sucampo Pharma Americas, LLCSucampo Pharmaceuticals, Inc.CompletedDry Age-related Macular DegenerationAustria
-
The New York Eye & Ear InfirmarySuspendedDry Age Related Macular DegenerationUnited States
-
Luxa Biotechnology, LLCNational Eye Institute (NEI); National Institutes of Health (NIH); Regenerative...RecruitingDry Age-related Macular DegenerationUnited States
-
CHABiotech CO., LtdTerminatedDry Age Related Macular DegenerationKorea, Republic of
-
Smilebiotek Zhuhai LimitedActive, not recruitingDry Age-related Macular DegenerationUnited States
-
Chinese Academy of SciencesBeijing Tongren HospitalUnknownDry Age-related Macular DegenerationChina
-
Apheresis Research InstituteCompletedDry Age Related Macular DegenerationGermany
-
i-Lumen Scientific, Inc.WithdrawnDry Age-related Macular Degeneration
Clinical Trials on Valeda PBM treatment
-
LumiThera, Inc.Active, not recruitingDry Age-related Macular DegenerationUnited States
-
Oslo University HospitalNot yet recruitingAge-Related Macular Degeneration | Photobiomodulation
-
Biolux Research Holdings, Inc.CompletedMalocclusionUnited States, Canada, Thailand
-
University of MalagaCompletedChronic Pain | FibromyalgiaSpain
-
The University of Texas Health Science Center,...CompletedPostoperative PainUnited States
-
University of FloridaNational Institute on Aging (NIA); University of ArizonaRecruitingCognitive Aging | Alzheimer Disease, Protection AgainstUnited States
-
Seaborough Life Science B.V.University of Groningen; Chrono@Work B.V.Not yet recruitingSleep Deprivation | Circadian Rhythm Disorders
-
LumiThera, Inc.RecruitingDry Age-related Macular DegenerationNorway
-
LumiThera, Inc.National Eye Institute (NEI)RecruitingDry Age-related Macular DegenerationUnited States